Atlas Trials

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

Clinical trial NCT00954915 · TERMINATED

Trial details

NCT number
NCT00954915
Sponsor
MacroGenics
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Psoriasis
Start date
2009-12-01
Primary completion
2010-07-01
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.